The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs
Abstract
Interview with Dr. Kevin Schulman on the recent approval of two PCSK9 inhibitors and what their prices could mean for insurance premiums. (09:12)Download Despite limitations in the data on the two new PCSK9 inhibitors, an FDA advisory committee has voted to approve alirocumab and evolocumab. But committee members emphatically stated that LDL cholesterol levels are not a reliable surrogate for cardiovascular benefit.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PCSK9 loss-of-function or pharmacologic inhibition lowers LDL cholesterol, but effects on plasma TG in treated patients are less robust and reproducible.
“PCSK9 loss-of-function or pharmacologic inhibition lowers LDL cholesterol, but effects on plasma TG in treated patients are less robust and reproducible (Everett et al., 2015).”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Everett et al., 2015
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/S0140-6736(05)67667-2 · DOI · Paper page
Cited by
Sorted by citations
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
Gromovsky, A. D., Schugar, R. C., Brown, A. L., Helsley, R. N., Burrows, A. C., Ferguson, D., Zhang, R., Sansbury, B. E., Lee, R. G., Morton, R. E., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309660 · Cited by 115
Lawler, P. R., Akinkuolie, A. O., Ridker, P. M., Sniderman, A. D., Buring, J. E., Glynn, R. J., Chasman, D. I., & Mora, S. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.264515 · Cited by 104
Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86
PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway
Liu, L.-S., Bai, X.-Q., Gao, Y., Wu, Q., Ren, Z., Li, Q., Pan, L.-H., He, N.-Y., Peng, J., & Tang, Z.-H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161136 · Cited by 38
γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor
Kim, K., Goldberg, I. J., Graham, M. J., Sundaram, M., Bertaggia, E., Lee, S. X., Qiang, L., Haeusler, R. A., Metzger, D., Chambon, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.010 · Cited by 26
Arunsak, B., Pratchayasakul, W., Amput, P., Chattipakorn, K., Tosukhowong, T., Kerdphoo, S., Jaiwongkum, T., Thonusin, C., Palee, S., Chattipakorn, N., et al. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108470 · Cited by 19
Metadata
- Authors
- Everett, B. M., Smith, R. J., & Hiatt, W. R.
- Affiliations
- From Harvard Medical School and Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital — both in Boston (B.M.E.); the Department of Medicine, Alpert Medical School, and the Department of Health Services, Policy, and Practice, School of Public Health, Brown University; and Ocean State Research Institute, Providence VA Medical Center — all in Providence, RI (R.J.S.); and the Department of Medicine, Division of Cardiology, University of Colorado School of...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-10-22
- Volume
- 373
- Issue
- 17
- Pages
- 1588-1591
- ISSN
- 0028-4793
- 1533-4406
- Cited by
- 112
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
